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and events attributed to OIC including the negative impact on job-related activi-
ties. Methods: A prospective longitudinal study conducted in the United States 
(US), Canada (CN), UK (UK), and Germany (GE) of patients with OIC who have been 
on opioid therapy for at least four weeks was conducted. OIC related medical history 
and health care resource use was collected from participants self report. The num-
ber of hours missed from work and the extent to which the work productivity and 
regular daily activities were affected was collected using the WPAI-SHP. Results: 
A total of 489 eligible participants (US: 238; CN: 38;, GE: 115; UK: 98). Back pain 
(77%) and joint pain (52%) were the most common pain diagnosis with an average 
duration of chronic pain and opioid medication use of 10 and 6 years respectively. 
27% of participants were currently employed. 18% of participants used at least 
one prescription laxative; 70% reported using at least one over-the-counter (OTC) 
laxative with the most common being stimulant laxatives (20%), osmotic laxatives 
(15%) and stool softeners (7%). 63% of participants reported discussing OIC with a 
health care provider, 3.0% reported a visit to the emergency room and 2.0% reported 
being admitted to a hospital because of their OIC during a 6-month time period. 
9% of employed participants reported missing an average of 4.6 hours per week 
because of problems associated with constipation and 32% reported impairment 
while working due to constipation. ConClusions: The cumulative impact of OTC 
use, physician office visits and the negative impact on work-related activities for 
OIC may be substantial.
PSY112
HealtH Care UtiliSation and SeleCted exPenditUreS aSSoCiated WitH 
neUroblaStoma in england
George S.1, Buckle J.2
1Milliman, Tampa, FL, USA, 2Milliman, London, UK
objeCtives: Neuroblastoma (NB) is a rare cancer of childhood, with nearly 90% of 
cases diagnosed by age 5 (ACS 2013). Our objective was to report the utilisation and 
cost of hospital services related to patients who have a diagnosis of NB and High 
Risk NB (HRNB) reported in an England dataset from a Clinical Commissioning 
Group (CCG) perspective. Methods: We used an England dataset covering hospi-
tal events (April 2010 - September 2013). Patients were included if they were under 
age 18 and had a hospital event with a primary or secondary diagnosis coded as 
International Classification of Disease 10thEdition (ICD10) C749. Newly diagnosed 
patients were identified if they had no hospital events in the first 4 months of 
the study period. From this newly diagnosed cohort we identified a HRNB cohort 
(bone marrow transplant) that included patients who had a high risk procedure 
that did not occur in the last 12 months of the study period. Cost and utilisation is 
reported from hospital admissions, emergency department visits, and outpatient 
attendances. Results: We observed 336 patients as newly diagnosed and an addi-
tional 33 patients were identified as HRNB. Newly diagnosed population inpatient 
admits were 12 per patient, compared with 22 per patient for the HRNB population. 
Total costs associated with the 336 newly diagnosed patients were £24.3m. Total 
costs associated with the 33 HRNB patients were £4.3m. Costs per HRNB patient 
(£130,303) were almost double the costs per newly diagnosed patient (£72,321). 
The average length of stay was 6 days for both sets of patients. ConClusions: 
To our knowledge this is the first retrospective analysis of NB cost and utilisation 
using encounter data from England. While it does not capture the entire costs to 
the England health care system, it indicates the level of resource intensity and 
cost at the CCG level.
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objeCtives: Patients’ profile undergoing intravenous immunobiological treatment 
is very limited. This study aimed to describe this information from the perspective of 
a Brazilian health plan, located in Fortaleza. Methods: This was a cross sectional 
study with data obtained from the HMO database as presented by Reis H et al at 
ISPOR 18th Annual Meeting. Eligible criteria for data analysis were patients being 
treated for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis 
(PsA) or Crohn’s disease (CD) who have received at least one dose of immunobiologi-
cal drug between March/2012 and October/2013. Data was stratified by indication 
(RA, AS, PsA and CD), patient weight and treatment profile (naïve versus non-naïve 
patients). Results: A total of 118 patients had been analyzed, with an average 
age of 51 years, and 66.9% (n = 79) of them being women. RA (n = 53,44,9%) and AS 
(n = 49,41,5%) were the most prevalent diseases being treated, followed by PsA 
(n = 13,11%) and CD (n = 3,2, 5%). The average weight of patients varied according 
to the disease being treated: 67 kg for RA and CD, and 70 kg for AS and PsA. It was 
observed that 65.5% patients were naïve to immunobiological drug, of which 73% 
initiated treatment with an anti-TNFa, being infliximab the most commonly pre-
scribed one (85.2%). As for patients who had already been previously treated, goli-
mumab and abatacept were the most commonly prescribed drugs (23%), whereas 
48.7% out of total were receiving the third immunobiogical drug and 35.9% were 
receiving the second one. ConClusions: The knowledge of patients profile and 
treatment information is the basis for any planning strategy in an HMO. Associated 
with costs, this data is crucial in supporting HMO board decisions on best treatment 
alternatives and so optimize the provided care.
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bursement status and availability of top 20 orphan drugs in Slovakia from 2005 
till 2012. Data were obtained from government sources. Results: We considered 
orphan drugs list (Cote and Keating, 2012) that exceeded 1 billion $ sales in 2008 
(globally) and compared molecules’ availability in Slovakia. Same molecules are 
among best selling 20 orphan drugs in Slovakia, with highest sale of 95 million EUR 
(Bevacizumab, 2005-2012) compared to lowest sale of 19 million EUR (Tacrolimus, 
2005-2012). It took from 1 (Imatinib) to 19 years (Glatiramer acetate) to be launched 
in Slovakia after orphan designation. Top 20 orphan drugs had average DOT 472 
EUR compared to total pharma market DOT average 0,43 EUR. From selected orphan 
drugs 60% had full (100%) reimbursement status and 40% were fully covered by 
hospital budgets. Only 4 of them were launched in Slovakia since 2005 (included), 16 
of them were launched from 1990 till 2004. Prices ranged from 330 EUR to 5800 EUR 
(ex-factory, one package, 2012). ConClusions: There are highly valuable incentives 
for industry to invest in to development of orphan drugs in EU. Current context of 
economic constraints in EU however justifies the need to pay close attention to the 
rationale of maintaining such incentives in the context of potential return on invest-
ments of companies offering high priced drugs. Top 20 orphan drugs in Slovakia 
have prices high above average and also full reimbursement status. We expect more 
restrictive drug policy measures in this field.
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objeCtives: In 2006 the American College of Medical Genetics (ACMG) developed 
a stakeholder survey to make recommendations for 84 rare conditions to be con-
sidered for mandatory newborn screening (NBS). Scores of 19 different surveyed 
attributes for each condition were totaled. These scores determined an entry point 
to an algorithm (EPA) that determined final recommendations (Core conditions, 
Secondary Targets or Not Recommended). Among these attributes was a contro-
versial one - non-patient benefits (NPB). Such attributes have historically not been 
considered in mandatory screening recommendations. This analysis examines 
how the exclusion of this attribute would affect recommendations. Methods: 
The ACMG report provided scores for individual attribute survey responses. We 
deleted the attribute score for NPB (0 to 100 points) and rescored the totals for 
each condition. We then assessed whether score changes were sufficient to alter 
the EPA and whether a different EPA would result in changes to the recommenda-
tions. Results: Six conditions had missing data. Of the 78 remaining, there were 
15 conditions (19%) whose initial total scores were capable of changing by enough 
in this exercise (maximum 100 point reduction) to change the EPA. Of those, 10 (67%) 
did change EPA and, of those, 3 (30%) changed final category (in all cases from Core 
to ST). Of the initial 29 recommended Core conditions, there would be a 10 percent 
reduction to 26 and an increase in Secondary Targets from 25 to 28. ConClusions: 
Including screening benefits to non-patients (family or society) is controversial 
and has not been standard in the past. We have shown that in the ACMG recom-
mendations, had no changes been made to the algorithm consequent to dropping 
non-patient benefits from consideration, 3 conditions would have changed from a 
Core recommendation for screening to only a Secondary Target.
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objeCtives: Orphan Drugs (ODs) are medicinal products intended for diagnosis, 
prevention or treatment of rare diseases. Access to ODs is crucial for patients’ health 
and quality of life. The aim of this study was to identify current problems and future 
challenges of patients’ access to ODs in Greece. Methods: A qualitative study took 
place between December 2013 and January 2014. Data were retrieved through semi-
structured interviews with six representatives of key stakeholders in Greece and 
policy documents identified through web searches using keywords “orphan drugs” 
and “rare diseases” in Greek. Web-based documents and transcribed interviews were 
content analyzed. Results: Delays in pricing and reimbursement of ODs in the 
Greek pharmaceutical market, budget cuts in hospitals and absence of patient reg-
istries constitute according to the analysis the greatest barriers in patients’ access 
to ODs. There are two main channels through which the patient can have access 
to an OD and it depends whether it is licensed in Greece or not. In the first case 
the patient can take the drug through the hospital or the pharmacy of EOPYY if it 
is not available at the hospital pharmacy and in the second case through a public 
sector organization (IFET). All cases are characterized by extensive bureaucracy and 
involvement of up to three organizations in order to receive the approval, a proce-
dure creating delays in patients’ access and risking their health. Also, the absence of 
a well-described procedure and lack of cooperation between the organizations and 
committees create further delays. ConClusions: Ensuring patients’ access to ODs 
in Greece is challenging especially during the economic crisis. Financial constraints 
and continuous legislative changes in the health system and the pharmaceutical 
market constitute important barriers to patients’ access. There is a need to describe, 
organize and communicate the pathway of patients’ access to ODs.
PSY111
Self rePorted HealtH Care reSoUrCe USe and indireCt eConomiC 
bUrden of oPioid indUCed ConStiPation (oiC)
Alemayehu B.1, Coyne K.S.2, King F.3
1AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 2Evidera, Bethesda, MD, USA, 
3AstraZeneca, Gaithersberg, MD, USA
objeCtives: To describe the health care resource utilization associated with the 
diagnosis, treatment, and general management of opioid-induced constipation (OIC) 
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objeCtives: Many obesity-associated diseases require intensive medical treat-
ment and are cause of a large proportion of health-related expenditures in 
Germany. Treatment of obesity includes nutritional, exercise and behavior ther-
apy, usually in combination. The goal of behavior therapy for obesity is to bring 
about a long-term alteration in eating and exercise habits of overweight and obese 
individuals. Depending of the severity of obesity, drug treatment may be indi-
cated. To evaluate the clinical and economic effectiveness of behaviour therapy 
for obesity considering approved drugs reducing weight, a Health Technology 
Assessment was carried out in the year 2008. This HTA was updated with publi-
cations up to 12/2013, along with new developments in behavior therapies and 
drugs. Methods: A systematic review was carried out using relevant electronic 
literature databases Publications chosen according to predefined criteria were 
evaluated by approved methodological standards of evidence-based medicine and 
health economics systematically and qualitatively. Results: Nine randomized 
controlled trials showed moderate but statistically significant reduction of weight 
in the intervention groups compared to control groups between 1.1 kg (at month 4) 
and 6.6 kg (at month 9). Studies with several examination time points resulted in 
statistically significant differences in the first evaluation time point (month 6) but 
not in the subsequent time points (month 12, 18, 24). The most frequent approach 
used for behavior therapy, was per phone or Email, two studies offered behavior 
therapy face-to-face. New behavior therapy approaches applied were techniques 
such as “Motivational Interviewing” and “Transtheoretical model”. No study was 
identified examining behavior therapy in combination with approved drug therapy. 
Two identified studies evaluating cost-effectiveness of behavior therapy per Email 
or phone showed cost-effectiveness for this kind of intervention but the results are 
biased due to a high rate of drop-outs. ConClusions: Behavior therapy consider-
ing new approaches is an effective method to reduce weight.
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objeCtives: To compare rheumatologists and dermatologists in terms of treat-
ment patterns and disease severity among PsA patients receiving their first bio-
logic in 5EU (UK/Germany/France/Italy/Spain). Methods: A medical chart-review 
study of psoriasis and PsA patients was conducted among rheumatologists and 
dermatologists in hospitals and private practices to collect de-identified data on 
disease and treatment characteristics. Physicians were screened for duration of 
practice (3-30yrs) and patient volume (≥ 2 Psoriasis/PsA biologic patients/month) 
and recruited from a large panel to be geographically representative in each country. 
Physicians abstracted charts of the next 5 consecutive Psoriasis/PsA patients in 
their respective sites. Treatment patterns and disease severity among PsA patients 
on their first line of biologic therapy treated by rheumatologists and dermatolo-
gists respectively were compared using descriptive statistics. Results: In Q42012, 
337 rheumatologists abstracted 527 PsA patient-charts (mean-age: 47.4yrs, male: 
51.4%) and 225 dermatologists abstracted charts of 109 psoriasis patients with PsA 
(mean-age: 49.0yrs, male: 56.0%; 55.1% were managed in conjunction with a rheu-
matologist; 67% were referred by GP/another dermatologist). Time to first biologic 
since diagnosis was 41.0mo/20.8mo for the rheumatologist/dermatologist-treated 
cohorts; disease severity at biologic initiation per physician judgment was (mild/
moderate/severe): rheumatologist-treated-cohort: 2.7%/60.2%/37.2%, dermatologist-
treated-cohort: 1.96%/46.08%/ 51.96%. In rheumatologist-treated-cohort: treatment 
naïve-12.9%, non-biological DMARDS-experienced: 74.0%; in dermatologist-treated 
cohort: treatment nainve-6.5%, 1-or-2 systemic-treatment-experienced prior to their 
first biologic-initiation: 69.5%. 38.7%/61.3% and 27.5%/72.5% had moderate-severe/
remission-mild disease-status among rheumatologist- and dermatologist-treated 
cohort respectively. Average current PASI score was higher among rheumatologist-
treated-cohort (18.7 vs. 10.3). ConClusions: Across the EU5, PsA treatment pat-
terns and disease severity varied based on physician specialty (rheumatologist vs. 
dermatologist); at biologic initiation dermatologists reported a significantly higher 
proportion of moderate/severe PsA patients than rheumatologists, but once first 
biologic treatment was well established dermatologists reported a lower disease 
burden then rheumatologists. Factors influencing these observed variations, includ-
ing optimal therapeutic approaches and care coordination between specialties to 
alleviate patient burden may warrant further scrutiny.
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objeCtives: To assess treatment patterns and disease severity of psoriasis patients 
receiving their first biologic-therapy in EU. Methods: A medical chart-review study 
of psoriasis patients was conducted in 4Q2013 in EU5 (UK/Germany/France/Italy/
Spain) among dermatologists to collect de-identified data on disease/treatment 
characteristics. Physicians were screened for duration-of-practice (3-30yrs) and 
patient-volume (≥ 2psoriasis biologic patients/month) and recruited from a large 
panel to be geographically representative in each country. Physicians abstracted the 
charts of next 5 consecutive psoriasis patients in their center/practice. Results from 
patients on their first biologic treatment were analyzed and comparisons made to 
EU5-averages. Results: 877 patient-charts were abstracted; 702 (80.0%) were on 
their first biologic (mean age: 47.3yrs, male: 64.1%). Prior to initiating biologic ther-
apy, immunomodulators/phototherapy were more widely used in UK than in other 
countries (90.3%/43.1% vs. 76.6%/30.4% overall, respectively); in Germany, fumarates/
objeCtives: Reimbursement decisions are often unsystematic and lack transpar-
ency, especially for orphan drugs. The objective of this study was to demonstrate 
whether multi-criteria decision analysis (MCDA) can support rational and explicit 
reimbursement decision process for orphan drugs in the Netherlands. Methods: 
An Analytic Hierarchy Process (AHP) framework was used in which Health Economics 
students were asked to weigh criteria used in drug reimbursement decisions through 
a web-based survey. Criteria were identified by a systematic literature review. Three 
different orphan drugs (alglucosidase alfa in infantile Pompe disease, canakinumab in 
cryopyrin-associated periodic syndromes and investigational product in rare disease) 
were also assessed by the students on their performance on these criteria. Criteria 
weights and performance scores were aggregated to an overall score for each orphan 
drug. Rank-ordering on overall scores prioritized the reimbursement of the three 
drugs. The students were also asked to assess the AHP survey on feasibility. Results: 
Nine criteria were identified and categorized in four domains; disease (burden of ill-
ness without treatment, life-threatening nature of the disease), drug (availability of 
other treatments, effectiveness of the drug, side effects and safety of the drug), finan-
cial aspects (annual costs of the drug per patient, budget impact, cost-effectiveness) 
and quality of evidence. The criterion ‘life-threatening nature of the disease’ was 
given the highest importance weight and budget impact the least. Alglucosidase alfa 
for treatment of infantile Pompe disease ranked highest of the three orphan drugs 
examined, particularly due to its performance in the disease and drug domains. The 
AHP survey was perceived as difficult by the respondents, which was confirmed by 
poor values for consistency ratios. ConClusions: Performing MCDA can enable 
explicit, transparent and auditable reimbursement decision-making for orphan drugs. 
However, its feasibility and applicability needs further investigation.
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objeCtives: To look at the affordability of orphan medications across Europe and 
whether payer attitudes to high-price medications are changing in the face of rising 
health care expenditure and tighter budgets. Methods: We conducted an online 
semi-quantitative survey of 10 European markets and the USA to understand how 
payers views and attitudes are changing in response to new treatments coming to 
market for rare and ultra-rare conditions. The payers selected for the survey hold 
or have held senior positions within their respective market institutions. The USA 
was included to provide international context to the European results. Results: 
82% of payers surveyed believe that the current approach to orphan drug pricing is 
unsustainable in the future and all respondents predict a tougher approach from 
payers going forward. 73% of payers do not believe that patent expiry alone will free 
up the necessary space for innovative orphan and ultra-orphan products. 82% of the 
payers surveyed believed that less than half of all orphan and ultra-orphan drugs 
coming to market are supported by an adequate evidence base for reimbursement. 
Although payers view rare diseases as a relatively high priority to fund, they are still 
behind therapy areas such as oncology and cardiovascular disease. ConClusions: 
As the financial performance of European countries begins to diverge, so do atti-
tudes towards the funding of orphan medicines. The increasing number of rare 
diseases is forcing payers to view orphan drugs in a new light and they are becom-
ing increasingly sceptical about the prices charged in relation to the clinical benefit 
offered. There is space for innovation; and patent expiry is freeing up funds, but rare 
diseases are competing with other therapy areas for limited budget. The bottom-line 
is that as rare disease spending becomes a higher proportion of pharmaceutical 
budgets, payers will take action to curb this trend.
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objeCtives: The lack of information and scientific knowledge of rare diseases (RDs) 
and orphan drug (ODs) could affect the quality of health care delivered to patients suf-
fering from rare diseases. The aim of this study was evaluation of the level of the general 
epidemiological knowledge among pharmacists regarding RDs and ODs as well as how 
that knowledge is influenced by information sources, education level and years of expe-
rience. Methods: The research design was based on a descriptive cross-sectional study. 
A questionnaire previously used in a pilot KAP study in Serbiain2012 was applied. The 
respondents were 182 pharmacists from public pharmacies in seven of 29 districts in 
Serbia. Individual level of knowledge was assessed by total number of correct answers 
from a maximum of 9, and overall knowledge was an average of the individual level of 
knowledge. Results: In total, 155 pharmacists were included in the full analysis set 
(response rate was 86.3%). Overall, the mean age was 43.4 years, and 94% were women. 
The average number of information sources regarding RD was 1.7%, and mostly one 
source out of five was used (56.1%). Pharmacists who were engaged in post-graduate 
programmes or completed such programmes tended to use more sources of information 
(69.2%) than those who were not involved in any such programme (41.9%). The mean 
value of correct answers about pharmacists’ knowledge regarding RD and OD was 4 ± 
1.77. Most pharmacists (n = 30, 19.35%) replied correctly to 6 questions. ConClusions: 
The results indicate that years of experience and age among pharmacists do not have 
influence to the overall knowledge about RD. The positive impact of education was evi-
dently, and for the better pharmaceutical care of RD patients the training of pharmacists 
to proper use of professional sources of information should be usefully.
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